Phoenix Migraine Relief: Join the MINT-E Episodic Migraine Clinical Trial at Arizona Neuroscience Research

09/30/2025 | Arizona Neuroscience Research |

If you’re searching for migraine treatment Phoenix AZ or a trusted research site in Arizona where you can access innovative therapies, you’ve found the right place. At Arizona Neuroscience Research (ANR) in Phoenix, we are committed to advancing the science of headache care through clinical trials that offer patients opportunities beyond standard treatment.

One of the most promising studies now enrolling is the MINT-E Episodic Migraine Study (NCT07018713). This clinical trial is testing a new investigational therapy for adults living with episodic migraine — defined as fewer than 15 headache days per month. The goal is to determine whether this treatment can reduce migraine frequency, severity, and impact on daily life.

For patients across Phoenix, Scottsdale, Tempe, Chandler, Mesa, Gilbert, Glendale, Peoria, Paradise Valley, and Ahwatukee, ANR provides direct access to innovative migraine research without having to leave Arizona.

Why Choose Arizona Neuroscience Research for Migraine Care

ANR is one of the leading clinical research centers in Arizona, specializing in neurology studies. We offer patients opportunities to access therapies not yet available to the public, while contributing to the advancement of medical science.

What Sets ANR Apart

  • Clinical Trial Expertise: ANR has participated in numerous national and international studies, providing patients with access to cutting-edge investigational treatments.
  • Convenient Location: Centrally located in Phoenix, ANR is easily accessible to patients across the Valley.
  • Comprehensive Care: Our research staff are trained in neurology and headache protocols, ensuring participants are monitored with the highest safety and care standards.
  • Patient-Centered Approach: We understand the burden of migraine and design our studies to minimize disruption while maximizing potential benefit.

Why Migraine Research Matters

  • Migraine affects more than 39 million Americans.
  • Episodic migraine can progress to chronic migraine if untreated.
  • Many patients don’t find sufficient relief from current medications, highlighting the need for new treatment options.

By joining the MINT-E study at ANR, patients in Phoenix have a chance to contribute to this progress while receiving study-related care at no cost.

Symptoms and Red Flags of Episodic Migraine

Migraines are not just “bad headaches.” They are a complex neurological disorder with multiple phases and symptoms.

Classic Migraine Symptoms

  • Throbbing or pulsating headache (often one-sided)
  • Light sensitivity (photophobia)
  • Sound sensitivity (phonophobia)
  • Nausea and vomiting
  • Visual aura (flashing lights, zig-zag lines, blind spots) in some patients

Episodic Migraine Defined

Episodic migraine means:

  • Headaches occur on fewer than 15 days per month
  • At least 5 attacks meet migraine criteria
  • Attacks last 4–72 hours if untreated

Red Flags for Emergency Care

Not all headaches are migraine. Seek immediate medical help if you experience:

  • A sudden, severe “thunderclap” headache
  • New headache with neurological symptoms (weakness, vision loss, confusion)
  • Headache with fever, stiff neck, or rash
  • New headaches after age 50

ANR educates participants on these distinctions to ensure safety during research participation.

Testing and Diagnosis in Phoenix

Before joining a clinical trial, accurate diagnosis is essential.

How Migraines Are Diagnosed

  • Clinical History: Detailed description of headache frequency, duration, and triggers
  • Neurological Exam: Assessing reflexes, strength, sensation, and coordination
  • Headache Diary: Tracking symptoms over weeks to confirm episodic pattern
  • Imaging (MRI/CT): Used to rule out secondary causes if red flags are present

Migraine Diagnostics at ANR

While ANR is a research site (not a general neurology clinic), participants in our studies receive:

  • Comprehensive screening visits to confirm eligibility
  • Safety evaluations including lab work and vitals
  • Ongoing monitoring during the study

Why Accurate Diagnosis Matters

Correctly distinguishing episodic migraine from chronic migraine or other headache disorders ensures:

  • Eligibility for the right trial (like MINT-E)
  • Appropriate safety oversight
  • Reliable data for advancing migraine research

Treatment Pathways: Standard Therapies and the MINT-E Study

For many patients, migraine treatment follows a trial-and-error path. Standard therapies help some but leave others struggling with frequent, disabling episodes. That’s why clinical research like the MINT-E Episodic Migraine Study (NCT07018713) is so important.

Current Standard Therapies

  1. Acute Treatments (taken at migraine onset):
    • Triptans (sumatriptan, rizatriptan)
    • Gepants (ubrogepant, rimegepant)
    • Ditans (lasmiditan)
    • NSAIDs or acetaminophen
  2. Preventive Treatments (taken daily or monthly):
    • CGRP inhibitors (erenumab, fremanezumab, galcanezumab, eptinezumab)
    • Beta-blockers (propranolol, metoprolol)
    • Antidepressants (amitriptyline, venlafaxine)
    • Anticonvulsants (topiramate, valproate)
    • Botox injections for chronic migraine
  3. Lifestyle Modifications:
    • Regular sleep and meal schedules
    • Hydration (especially important in Arizona heat)
    • Stress reduction techniques (yoga, meditation, breathing exercises)

The MINT-E Clinical Trial

The MINT-E study is investigating an investigational treatment specifically for episodic migraine. Participants may benefit from:

  • Access to an innovative therapy not yet available outside of research
  • Close monitoring and care from experienced research staff
  • Study-related evaluations at no cost
  • Contribution to the global understanding of migraine treatment

Eligibility typically includes:

  • Adults aged 18–65
  • History of migraine for at least one year
  • Between 4 and 14 migraine days per month
  • Not currently enrolled in another investigational migraine trial

Final eligibility is determined during the ANR screening process.

Lifestyle in Arizona: Migraine Triggers and Prevention

Arizona patients face unique migraine challenges due to climate and environment.

Common Triggers in the Desert Southwest

  • Heat and Dehydration: Even mild dehydration can trigger migraines.
  • Monsoon Weather Changes: Rapid barometric pressure shifts can precipitate attacks.
  • Bright Sunlight: Strong UV exposure can worsen photophobia.
  • Seasonal Allergies: Pollen and dust storms increase inflammation.

Practical Prevention Strategies

  • Carry a refillable water bottle at all times.
  • Wear polarized sunglasses and wide-brimmed hats.
  • Use indoor cooling strategies during summer peaks.
  • Keep a migraine diary to identify and avoid triggers.
  • Consider blue-light blocking glasses for screen use.

Research and Second Opinions at ANR

Why Research Participation Matters

Every FDA-approved migraine treatment available today was once part of a clinical trial. By participating in research at ANR, patients:

  • Gain access to promising new options
  • Receive structured care with frequent follow-ups
  • Help future migraine patients in Phoenix and beyond

Second Opinions and Trial Opportunities

Patients often come to ANR after trying standard therapies without success. A second opinion at a research site can uncover:

  • Eligibility for migraine studies like MINT-E
  • Education on cutting-edge therapies
  • A fresh perspective on management strategies

ANR’s role is not to replace primary neurology care but to complement it through access to innovation.

Frequently Asked Questions (FAQs)

1. What is episodic migraine?
Episodic migraine is defined as fewer than 15 headache days per month, with migraine attacks lasting 4–72 hours if untreated.

2. How is episodic migraine different from chronic migraine?
Chronic migraine means 15 or more headache days per month for at least three months, with at least 8 days having migraine features.

3. What is the MINT-E clinical trial?
MINT-E is a research study testing a new investigational treatment for adults with episodic migraine.

4. Do I have to pay to join the study?
No. Study-related care, visits, and investigational medication are provided at no cost to participants.

5. Can I stay on my current migraine medication?
Some medications may be allowed; others may require adjustment. ANR staff will review this during screening.

6. Who can join the study?
Adults 18–65 with a migraine history and 4–14 migraine days per month. Final eligibility is determined at ANR.

7. What are the risks of joining a trial?
All research studies carry potential risks. Participants are fully informed and monitored for safety throughout.

8. Where is ANR located?
ANR is located in Phoenix, serving patients across the Valley including Scottsdale, Tempe, Chandler, Mesa, Gilbert, Glendale, Peoria, Paradise Valley, and Ahwatukee.

9. Why should I join a migraine trial at ANR?
To access innovative therapies, receive close study-related care, and help advance migraine science.

10. How do I sign up?
Call ANR directly or visit our website to learn more about the MINT-E study and schedule a screening.

How to Enroll in the MINT-E Study at ANR

If you or someone you love suffers from episodic migraine, now is the time to explore new possibilities.

  • Phone: Call ANR today to speak with our research staff.
  • Website: Visit azneuroscienceresearch.com
  • Location: Phoenix, Arizona (serving the entire Valley)

Enrolling in a clinical trial is not just about your health today — it’s about shaping the future of migraine care for tomorrow.

On-Page SEO Optimization

Meta Title: Migraine Treatment Phoenix AZ | Join the MINT-E Episodic Migraine Study at ANR
Meta Description: Arizona Neuroscience Research (ANR) in Phoenix is enrolling participants for the MINT-E Episodic Migraine Clinical Trial. Learn more about migraine relief and research today.
OG Title: Episodic Migraine Research in Phoenix – ANR
OG Description: Participate in migraine clinical trials at ANR. Explore the MINT-E study for episodic migraine and access innovative treatment options in Arizona.

Schema (JSON-LD):

  • ClinicalTrial schema with NCT07018713 reference
  • MedicalResearchStudy schema with ANR as sponsor site

Internal Links (suggested):

  • /phoenix-epilepsy-breakthrough-join-the-power-1-focal-epilepsy-study-at-anr
  • /chronic-migraine-relief-in-phoenix-enroll-in-the-mint-c-clinical-trial-at-anr
  • /phoenix-migraine-relief-join-the-mint-e-episodic-migraine-study-at-anr-2

External References:

  • ClinicalTrials.gov: NCT07018713
  • American Migraine Foundation: Migraine Overview
  • NIH: Migraine Research Updates

SEO Hashtags for Social Media

#MigraineTreatmentPhoenix #EpisodicMigraineArizona #HeadacheSpecialistPhoenix #MigraineReliefPhoenix #ANRResearch #ClinicalTrialsPhoenix #MigraineStudyArizona #PhoenixNeurologyResearch #MigrainePreventionAZ #JoinMINTStudy #ValleyMigraineRelief #ArizonaNeurologyResearch #PhoenixClinicalTrials #EpisodicMigraineCare #InnovativeMigraineTherapies #NeurologyResearchPhoenix #BestMigraineResearchAZ #ArizonaHeadacheRelief #MigraineSolutionsPhoenix #ParticipateInResearchAZ

Recent Posts

Categories